民生证券担任维康药业督导机构存违规行为被监管警示

Core Viewpoint - The Zhejiang Securities Regulatory Bureau has issued administrative regulatory measures against Minsheng Securities for violations during its continuous supervision of Weikang Pharmaceutical's IPO process, highlighting deficiencies in internal controls and due diligence [2][3]. Group 1: Regulatory Actions - Minsheng Securities failed to adequately address the abnormal delays in construction projects and conducted insufficient verification procedures [2]. - The regulatory measures include a warning letter issued to Minsheng Securities, with representatives Ren Shaozhong and Zhong Desong held primarily responsible for the violations [3]. - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Weikang Pharmaceutical and its actual controller Liu Zhongliang for suspected violations of information disclosure laws [3]. Group 2: Financial Penalties - Weikang Pharmaceutical has been fined 5 million yuan and ordered to rectify its actions, while Liu Zhongliang has been fined 7 million yuan for his involvement in the misconduct [4]. Group 3: Company Performance - Weikang Pharmaceutical, which went public in August 2020, has experienced a decline in performance, reporting losses for two consecutive years in 2023 and 2024 [5]. Group 4: Corporate Changes - Guolian Securities has received approval to acquire Minsheng Securities, with the integration of investment banking operations and client migration announced at the end of September [6]. - As of September 23, 2025, various investment banking projects of Minsheng Securities will be transferred to Guolian Minsheng [6].